Jin Rong Jie·2025-08-13 08:55Core Viewpoint - The article highlights the performance of the Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd., emphasizing its significant A/H share premium and its ongoing innovations in the biopharmaceutical sector [1][2]. Company Overview - Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1] - The company focuses on innovative research, development, production, and sales in the biopharmaceutical field, aiming to become a leading innovation enterprise centered on intellectual property [1]. Market Performance - On August 13, the Shanghai Composite Index rose by 0.48% to close at 3683.46 points, while the Hang Seng Index increased by 2.58% to 25613.67 points [1]. - Fudan Zhangjiang's A-shares closed at 10.59 yuan, with a gain of 0.67%, while its H-shares closed at 3.92 HKD, experiencing a decline of 1.75% [1]. Competitive Advantage - The company has developed a competitive edge through continuous innovation in areas such as gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage technology drugs [1]. - Fudan Zhangjiang has participated in several national key science and technology projects, including the "National Key Technology R&D Program," "National High Technology Research and Development Program (863 Program)," and the "Major New Drug Creation" technology major special project [1].